Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials.

Authors
Category Primary study
JournalAnnals of the rheumatic diseases
Year 2002
This article has no abstract
Epistemonikos ID: a628057c66367aaa7de5f5252cd3f6c521246f61
First added on: Nov 15, 2012